21 May 2022: Clinical Research
Curative Analysis of Patients with Hepatocellular Carcinoma Using Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation
Yifan Li AE , Diwen Zhu BCD , Weixin Ren AE* , Junpeng Gu BCD , Weizheng Ji BCD , Haixiao Zhang BCD , Yingjun Bao BCD , Gengfei Cao BCD , Asihaer Hasimu BCDDOI: 10.12659/MSM.936246
Med Sci Monit 2022; 28:e936246
Table 3 Association of the high-risk group with progression or death in 1 year compared with the low-risk group.
| Model 1 | Model 2 | Model 3 | ||||
|---|---|---|---|---|---|---|
| HR | P | HR | P | HR | P | |
| High-risk group compared to low-risk group | 6.70 (3.647–12.309) | 6.651 (3.620–12.221) | 12.232 (6.005–24.916) | |||
| HR – hazard risk; CI – confidence interval. did not adjust for confounders; adjusted the number of TACE during the first treatment and LDH; adjusted the number of TACE during the first treatment, LDH, tumor location, tumor size, PVTT, hepatitis, CP, BCLC, and CNLC. | ||||||